During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial ...

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than ...

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical ...

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing ...

Panelists discuss the shift toward patient-centered outcomes in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis treatment, emphasizing quality of life and symptom relief alongside ...

Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ...

Current guidelines suggest limiting diagnostic testing for chronic spontaneous urticaria when no clear cause is suspected, though biomarkers and biopsies are emerging as tools to predict treatment ...

Participants performed touchscreen-based reaching tasks while wearing wireless motion sensors, which recorded linear acceleration, angular velocity, and roll-pitch-yaw orientation at millisecond ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.